PMID- 17994445
OWN - NLM
STAT- MEDLINE
DCOM- 20080117
LR  - 20131121
IS  - 0886-022X (Print)
IS  - 0886-022X (Linking)
VI  - 29
IP  - 7
DP  - 2007
TI  - Effects of long-term pravastatin treatment on serum and urinary monocyte 
      chemoattractant protein-1 levels and renal function in type 2 diabetic patients 
      with normoalbuminuria.
PG  - 791-6
AB  - To explore the renoprotective and anti-inflammatory effects of pravastatin, we 
      analyzed the changes in renal function and urinary monocyte chemoattractant 
      protein-1 (MCP-1) level as a renal tubulointerstitial inflammatory biomarker and 
      serum MCP-1 level as a systemic inflammatory biomarker following the introduction 
      of treatment with 10 mg/day of pravastatin in 10 hyperlipidemic type 2 diabetic 
      patients with normoalbuminuria. Twelve months of the pravastatin treatment did 
      not affect urinary levels of albumin, transferrin, N-acetylglucosaminidase, or 
      MCP-1 in the hyperlipidemic diabetic patients, whereas the treatment 
      significantly reduced serum levels of MCP-1 in the patients. The pravastatin 
      treatment effectively lowered low-density lipoprotein cholesterol (LDL-C) levels 
      in the hyperlipidemic diabetic patients to levels nearly to those in 11 
      non-hyperlipidemic type 2 diabetic patients with normoalbuminuria. Interestingly, 
      serum MCP-1 levels were significantly lower in the hyperlipidemic patients 
      treated with pravastatin than in the non-hyperlipidemic patients. No significant 
      correlation was observed between serum LDL-C and MCP-1 levels in all the data in 
      the hyperlipidemic patients before and after the pravastatin treatment and in the 
      non-hyperlipidemic patients. These results collectively indicate that pravastatin 
      may ameliorate systemic vascular inflammation rather than local renal 
      inflammation in hyperlipidemic type 2 diabetic patients with normoalbuminuria, 
      independent of its cholesterol-lowering effects.
FAU - Fujita, Hiroki
AU  - Fujita H
AD  - Division of Endocrinology, Metabolism and Geriatric Medicine, Department of 
      Internal Medicine, Akita University School of Medicine, Akita, Japan. 
      hirofuji@gipc.akita-u.ac.jp
FAU - Koshimura, Jun
AU  - Koshimura J
FAU - Sato, Takehiro
AU  - Sato T
FAU - Miura, Takeshi
AU  - Miura T
FAU - Sasaki, Hiroshi
AU  - Sasaki H
FAU - Morii, Tsukasa
AU  - Morii T
FAU - Narita, Takuma
AU  - Narita T
FAU - Kakei, Masafumi
AU  - Kakei M
FAU - Ito, Seiki
AU  - Ito S
FAU - Yamada, Yuichiro
AU  - Yamada Y
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - KXO2KT9N0G (Pravastatin)
SB  - IM
MH  - Aged
MH  - Albuminuria/urine
MH  - Chemokine CCL2/*blood/*urine
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus, Type 2/*physiopathology/urine
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Kidney/*drug effects/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Pravastatin/*therapeutic use
EDAT- 2007/11/13 09:00
MHDA- 2008/01/18 09:00
CRDT- 2007/11/13 09:00
PHST- 2007/11/13 09:00 [pubmed]
PHST- 2008/01/18 09:00 [medline]
PHST- 2007/11/13 09:00 [entrez]
AID - 783646915 [pii]
AID - 10.1080/08860220701543056 [doi]
PST - ppublish
SO  - Ren Fail. 2007;29(7):791-6. doi: 10.1080/08860220701543056.